Why Ultragenyx Pharma Stock Is Trading Higher Premarket Today
Portfolio Pulse from Vandana Singh
Ultragenyx Pharmaceutical (RARE) and Mereo BioPharma Group (MREO) announced positive data from the Phase 2 portion of the Orbit study of setrusumab for osteogenesis imperfecta (OI). The drug demonstrated significant increases in serum P1NP levels and improvement in bone mineral density (BMD) by three months.
June 06, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mereo BioPharma Group's stock is trading higher premarket due to positive Phase 2 data from the Orbit study of setrusumab for osteogenesis imperfecta.
The positive Phase 2 data for setrusumab indicates that the drug is effective in treating osteogenesis imperfecta, which could lead to increased demand and potential revenue for Mereo BioPharma. This news is likely to have a positive short-term impact on MREO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Ultragenyx Pharmaceutical's stock is trading higher premarket due to positive Phase 2 data from the Orbit study of setrusumab for osteogenesis imperfecta.
The positive Phase 2 data for setrusumab indicates that the drug is effective in treating osteogenesis imperfecta, which could lead to increased demand and potential revenue for Ultragenyx. This news is likely to have a positive short-term impact on RARE's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100